# Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

> **NCT02490488** · PHASE2,PHASE3 · COMPLETED · sponsor: **AB Science** · enrollment: 248 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Gemcitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02490488
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02490488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02490488, "Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02490488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*